Preclinical and clinical studies have demonstrated the efficacy of EGFR-targeted therapies, such as cetuximab and panitumumab, in improving clinical outcomes in HNSCC patients (43–45). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.